The classic approach to cancer treatment was to switch off the proteins driving the disease. A team at Stanford School of Medicine tried the exact opposite: instead of stopping the protein that fuels aggressive blood cancers, they converted it into a mechanism that kills the cell outright.

2

In the lab, this experimental molecule reduced lymphoma tumors in mice to zero within 11 days.

2
2

Why does BCL6 get stuck in cells?

The survival of diffuse large B-cell lymphoma, the most common form of non-Hodgkin lymphoma, depends heavily on a protein called BCL6. In a healthy immune response, this protein temporarily silences cell-proliferation and death genes; once the threat passes, it should switch off and the hesitation loop closes.

In cancerous cells, however, this switch